These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21738109)

  • 1. Levofloxacin revisited.
    Med Lett Drugs Ther; 2011 Jul; 53(1368):55. PubMed ID: 21738109
    [No Abstract]   [Full Text] [Related]  

  • 2. [Modern fluoroquinolones (ciprofoxacin, levofloxacin) and the treatment of skin and soft tissue infections].
    Iakovlev VP; Svetukhin AM; Blatun LA; Ukhin SA
    Antibiot Khimioter; 2004; 49(8-9):57-65. PubMed ID: 15727148
    [No Abstract]   [Full Text] [Related]  

  • 3. Sparfloxacin and levofloxacin.
    Med Lett Drugs Ther; 1997 Apr; 39(999):41-3. PubMed ID: 9137295
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment in general practice. Effective, well tolerated therapy].
    MMW Fortschr Med; 2000 Sep; 142(37):58-9. PubMed ID: 11026226
    [No Abstract]   [Full Text] [Related]  

  • 5. Once-daily ofloxacin for hospitalised patients with severe bacterial infections.
    Landau Z; Arcavi L; Resnitzky P
    Drugs; 1995; 49 Suppl 2():472-3. PubMed ID: 8549404
    [No Abstract]   [Full Text] [Related]  

  • 6. [Levofloxacin. Clinical experience with long-term treatment of osteoarticular infections].
    Azanza JR; Cárdenas E; Muñóz MJ; Valentí JR; García-Quetglas E
    Rev Med Univ Navarra; 2002; 46(3):23-7. PubMed ID: 12685113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levofloxacin.
    Norrby SR
    Expert Opin Pharmacother; 1999 Nov; 1(1):109-19. PubMed ID: 11249554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adverse drug reaction and rational use of levofloxacin: a prospective study].
    Zhang Z; Zhen J; Zhan S
    Zhonghua Liu Xing Bing Xue Za Zhi; 2001 Dec; 22(6):405-7. PubMed ID: 11851050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levofloxacin-induced toxic epidermal necrolysis in an elderly patient.
    Digwood-Lettieri S; Reilly KJ; Haith LR; Patton ML; Guilday RJ; Cawley MJ; Ackerman BH
    Pharmacotherapy; 2002 Jun; 22(6):789-93. PubMed ID: 12066972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase IV study (postmarketing surveillance) of Tarivid (ofloxacin) in China.
    Li JT; Yoshida M; Nakatsuka K
    Drugs; 1995; 49 Suppl 2():474-6. PubMed ID: 8549405
    [No Abstract]   [Full Text] [Related]  

  • 11. [The safety profile and tolerance of levofloxacin].
    Honorato J; Caballero E; Campanero MA; Escolar M
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():44-6. PubMed ID: 10563111
    [No Abstract]   [Full Text] [Related]  

  • 12. [Levofloxacin-related Stevens-Johnson syndrome].
    Fernández Arenas O; López Lunar E; Gutiérrez García M; Hidalgo Correas FJ; García Díaz B
    Farm Hosp; 2012; 36(1):53-5. PubMed ID: 21514868
    [No Abstract]   [Full Text] [Related]  

  • 13. [Levofloxacin in the treatment of respiratory infections].
    Iakovlev SV; Iakovlev VP
    Antibiot Khimioter; 2002; 47(8):32-42. PubMed ID: 12515095
    [No Abstract]   [Full Text] [Related]  

  • 14. [Tolerability and safety of levofloxacinin long-term treatment].
    Ortega M; Soriano A; García S; Almela M; Alvárez JL; Tomás X; Mensa J; Soriano E
    Rev Esp Quimioter; 2000 Sep; 13(3):263-6. PubMed ID: 11086274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Levofloxacin for prevalent infections in primary care medicine].
    Redondo Sánchez J
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():29-33. PubMed ID: 10563108
    [No Abstract]   [Full Text] [Related]  

  • 16. A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis.
    Adelglass J; Jones TM; Ruoff G; Kahn JB; Wiesinger BA; Rielly-Gauvin K; Siu CO
    Pharmacotherapy; 1998; 18(6):1255-63. PubMed ID: 9855324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of levofloxacin 200 mg 3 times daily in the treatment of bacterial lower respiratory tract infections.
    Kawai T
    Drugs; 1995; 49 Suppl 2():416-7. PubMed ID: 8549383
    [No Abstract]   [Full Text] [Related]  

  • 18. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
    Schwab IR; Friedlaender M; McCulley J; Lichtenstein SJ; Moran CT;
    Ophthalmology; 2003 Mar; 110(3):457-65. PubMed ID: 12623805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinico-pharmacologic aspects of the use of ofloxacin].
    Kukes VG; Belitskaia RA; Dubova MN; Krasavina MIu; Posrednikova TA
    Antibiot Khimioter; 1996; 41(9):39-42. PubMed ID: 9005783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen.
    Olapade-Olaopa EO; Adebayo SA
    J Urol; 2006 Jun; 175(6):2365-6; author reply 2366. PubMed ID: 16697876
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.